Doxorubicin lung cancer

Anthracyclines Doxorubicin/ adriamycin Melanoma, Ovarian carcinoma, T-cell lymphoma, Colon carcinoma, B-cell lymphoma, Various disseminated refractory malignandes, Breast cancer, Lung cancer, Pancreatic cancer, Liver cancer, Neuroblastoma... 

Volm M, Pommerenke EW (1995) Associated expression of protein kinase C with resistance to doxorubicin in human lung cancer. Anticancer Res 15 463-466... 

Doxorubicin is one of the most effective agents used in the treatment of carcinomas of the breast, ovary, endometrium, bladder, and thyroid and in oat cell cancer of the lung. It is included in several combination regimens for diffuse lymphomas and Hodgkin s disease. Doxorubicin can be used as an alternative to daunorubicin in acute leukemias and is useful in Ewing s sarcoma, osteogenic sarcoma, soft-tissue sarcomas, and neuroblastoma. Some activity has been reported in non-oat cell lung cancer, multiple myeloma, and adenocarcinomas of the stomach, prostate, and testis. 

Hexamethylmelamine is useful for the treatment of ovarian adenocarcinoma and is frequently combined with cyclophosphamide, cisplatin, and doxorubicin in the treatment of this tumor. It also has some activity against small cell lung cancer. 

Epirubicin (FARMORUBICIN) is structurally similar to doxorubicin and is similarly effective in the treatment of breast cancer, lung cancer and lymphoma. 

Doxorubicin Oxygen free radicals bind to DNA causing single- and double-strand DNA breaks inhibits topoisomerase II intercalates into DNA Breast cancer, Hodgkin s and non-Hodgkin s lymphoma, soft tissue sarcoma, ovarian cancer, non-small cell and small cell lung cancer, thyroid cancer, Wilms tumor, neuroblastoma Nausea, red urine (not hematuria) Cardiotoxicity (see text), alopecia, myelosuppression, stomatitis... 

O Connor, R., et al. 2004. Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Res 24 457. 

In vitro studies with several tumor cell lines have shown vitamin C to enhance the cytotoxic activity of doxorubicin, cisplatin, paclitaxel, dacarbazine, 5-FU, and bleomycin. Vitamin C has also been shown to increase drug accumulation and to partially reverse vincristine resistance of human nonsmall-cell lung cancer cells. 

A. Imran and T. M. Allen. Antibody-mediated specific binding and cytotoxicity of liposome-entrapped Doxorubicin to lung cancer cells in vino. Cancer Res. 52 ... 

Caelyx is liposomal doxorubicin very well used as a treatment of choice for a number of cancers with good tolerability and antitumor activity, as has been demonstrated in many phase I or II clinical trials. One such example is the conduct of phase I study of Caelyx (PEGylated liposomal doxorubicin, 25 M) mg/m2) in combination with cyclophosphamide (750-1000 mg/m2) and vincristine (1.2 mg/m2) every 21 days in patients with relapsed or refractory small cell lung cancer [442], The suggested doses were CaelyxTM 35 mg/m2, cyclophosphamide 750 mg/m2, and vincristine 1.2 mg/m2 intravenously every 21 days. This combination was well tolerated... 

Moreira, J. N., and Gaspar, R. (2004), Antagonist G-mediated targeting and cytotoxicity of liposomal doxorubicin in NCI-H82 variant small cell lung cancer, Braz J. Med. Biol. Res., 37,1185-1192. 

Leighl, N., Burkes, R. L., Dancey, J. E., Lopez, P. G., Higgins, B. P., Walde, P L. D., Rudinskas, L. C., Rahim, Y. H., Rodgers, A., Pond, G. R., and Shepherd, F. A. (2003), A phase I study of pegylated liposomal doxorubicin (Caelyx ) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer, Clin. Lung Cancer, 5,107-112. 

Masuno T, Kishimoto S, Ogura T, Honma T, Niitani H, Fukuoka M, Ogawa N. A comparative trial of LC9018 plus doxorubicin and doxorubicin alone for the treatment of malignant pleural effusion secondary to lung cancer. Cancer 1991 68(7) 1495-500. 

Rushing DA, Raber SR, Rodvold KA, Piscitelh SC, Plank GS, Tewksbury DA. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 1994 74(3) 834-41. 

Docetaxel is a taxane that is used in combination with doxorubicin in the treatment of metastatic breast cancer and as a single agent in metastatic lung cancer. 

Forty patients with lung cancer, treated with a combination of cisplatin, mitomycin, vinblastine, doxorubicin, cyclosphosphamide, and methotrexate, had a significant post-treatment increase in fibrinopeptide A and a fall in fibrinolytic activity, reflected by a fall in functional tissue activator this appeared to be cumulative, depending on the extent of drug exposure (184). 

Leighl NB +, Clin Lung Cancer 5(2), 107 (with doxorubicin and vincristine)... 

Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992 10 282-291. 

Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA (1998) Synergistic toxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 78 1035-1042... 

The same lung cancer cell line was used to investigate the effects of flavopiridol when mixed with other compounds used widely in cancer chemotherapy, these compounds being paclitaxel, cytarabine, topotecan, doxorubicin, cisplatin and etoposide and 5-fluorouracil [24]. Four... 

---